GNLX
GENELUX Corp
$2.93
0.00%
$131.4M
No data for this timeframe.
Vol
Market Cap$131.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders7 funds
Inst. Value$8.9M
Inst. Activity1 buys / 2 sells
Insider Activity0B / 12S
Insider Net $-$86.4K
SEC Reports4
Press Releases1
Recent Activity
Jun 5, 2026
SEC
Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sales over a 7-day wind
CLUSTER — Impact 2/10
Jun 3, 2026
Insider
Smalling Ralph sold 192 shares
Head of Regulatory @ $2.93 ($562.56)
Jun 1, 2026
Insider
Thomas John sold 10,000 shares
Director @ $2.98 ($29.8K)
May 13, 2026
SEC
Two insiders at Genelux Corp sold a total of $9K in open-market sales on May 11, 2026, including the CEO and Head of Reg
CLUSTER — Impact 2/10
May 13, 2026
earnings_calendar
GNLX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
Insider
Smalling Ralph sold 270 shares
Head of Regulatory @ $2.98 ($804.49)
Apr 29, 2026
SEC
GENELUX Corp filed a DEFA14A (additional definitive proxy soliciting materials) on April 29, 2026. The filing contains n
DEFA14A — Impact 2/10
Inst.
MORGAN STANLEY — ADD
92,189 shares ($401.9K)
Price Targets
$17.50
+487.2% upside
Strong Buy
Current $2.98
Low $10.00
Median $16.00
High $31.00
6 analysts
$10.00
$31.00
Analyst Ratings
2Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 20, 2026 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +2.5% | $-0.22 — $-0.18 | 2% YoY | 6 |
| Next Q | $-0.20 ▲ +2.4% | $-0.23 — $-0.18 | 3% YoY | 6 |
| Current FY | $-0.81 ▲ +0.6% | $-0.91 — $-0.74 | 5% YoY | 6 |
| Next FY | $-0.76 ▲ +7.4% | $-0.93 — $-0.56 | 7% YoY | 5 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sales over a 7-day wind
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Genelux Corp sold a total of $9K in open-market sales on May 11, 2026, including the CEO and Head of Reg
May 13, 2026
MIXED
Press
6/10
Genelux reported its 2025 financial results, showing a narrowed net loss and increased R&D spend due to its Phase 3 ovar
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $6.8M | — |
| BANK OF AMERICA CORP | $1.5M | — |
| MORGAN STANLEY | $401.9K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $109.0K | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $100.7K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Smalling Ralph | SELL | $562.56 |
| Jun 1, 2026 | Thomas John | SELL | $29.8K |
| May 11, 2026 | Smalling Ralph | SELL | $804.49 |
| May 11, 2026 | Zindrick Thomas | SELL | $8.2K |
| May 11, 2026 | Yu Yong | SELL | $1.8K |
7 institutional holders with $8.9M total value (2,033,147 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,551,449 | $6.8M | 76.3% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 336,021 | $1.5M | 16.5% | — |
| 3 | MORGAN STANLEY | 92,189 | $401.9K | 4.5% | ADD +52.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 25,000 | $109.0K | 1.2% | NEW |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 23,100 | $100.7K | 1.1% | TRIM -63.3% |
| 6 | WELLS FARGO & COMPANY/MN | 4,485 | $19.6K | 0.2% | — |
| 7 | FMR LLC | 903 | $3.9K | 0.0% | TRIM -25.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 60,644 | 92,189 | +52.0% | $401.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 62,900 | 23,100 | -63.3% | $100.7K | 2025-Q4 |
| FMR LLC | TRIM | 1,217 | 903 | -25.8% | $3.9K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 22,700 | 62,900 | +177.1% | $264.2K | 2025-Q3 |
| UBS Group AG | TRIM | 71,224 | 27,779 | -61.0% | $116.7K | 2025-Q3 |
| FMR LLC | ADD | 903 | 1,217 | +34.8% | $5.1K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 24,992 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | TRIM | 1,300 | 903 | -30.5% | $2.6K | 2025-Q2 |
| MORGAN STANLEY | ADD | 53,840 | 69,010 | +28.2% | $186.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 25,091 | 68,136 | +171.6% | $184.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 19,454 | 67,990 | +249.5% | $183.6K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 25,000 | — | $67.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 14,551 | 19,300 | +32.6% | $52.1K | 2025-Q1 |
| MORGAN STANLEY | ADD | 29,924 | 53,840 | +79.9% | $127.1K | 2024-Q4 |
| UBS Group AG | TRIM | 40,089 | 25,091 | -37.4% | $59.2K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 58,566 | 19,454 | -66.8% | $45.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 122,537 | 14,551 | -88.1% | $34.3K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 89,191 | 29,924 | -66.4% | $70.9K | 2024-Q3 |
5 unique insiders with 12 transactions. Net insider value: -$86.4K ($0.00 bought, $86.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Smalling Ralph | Head of Regulatory | SELL | 192 | $2.93 | $562.56 |
| Jun 1, 2026 | Thomas John | Director | SELL | 10,000 | $2.98 | $29.8K |
| May 11, 2026 | Smalling Ralph | Head of Regulatory | SELL | 270 | $2.98 | $804.49 |
| May 11, 2026 | Zindrick Thomas | President and CEO | SELL | 2,798 | $2.94 | $8.2K |
| May 11, 2026 | Yu Yong | Chief Scientific Officer | SELL | 605 | $2.97 | $1.8K |
| May 11, 2026 | Cappello Joseph | Chief Technical Officer | SELL | 605 | $2.97 | $1.8K |
| Mar 25, 2026 | Smalling Ralph | Head of Regulatory | SELL | 240 | $2.51 | $602.40 |
| Mar 24, 2026 | Smalling Ralph | Head of Regulatory | SELL | 345 | $2.42 | $834.90 |
| Mar 24, 2026 | Cappello Joseph | Chief Technical Officer | SELL | 906 | $2.42 | $2.2K |
| Mar 24, 2026 | Yu Yong | SVP, Clinical Development | SELL | 906 | $2.42 | $2.2K |
| Mar 24, 2026 | Zindrick Thomas | President and CEO | SELL | 3,582 | $2.42 | $8.7K |
| Mar 2, 2026 | Thomas John | Director | SELL | 10,000 | $2.90 | $29.0K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 2.3/10.
NEUTRAL
CLUSTER
2/10
Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sal
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Genelux Corp sold a total of $9K in open-market sales on May 11, 2026, including the
May 13, 2026
NEUTRAL
DEFA14A
2/10
GENELUX Corp filed a DEFA14A (additional definitive proxy soliciting materials) on April 29, 2026. T
Apr 29, 2026
NEUTRAL
CLUSTER
3/10
Five GENELUX Corp insiders, including the CEO and CTO, sold shares in the past week, with total open
Mar 26, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 2 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.50 mean target
+487.2% upside
Strong Buy (3.00)
$10.00 Low
$31.00 High
| Metric | Value |
|---|---|
| Current Price | $2.98 |
| Target Low | $10.00 |
| Target Mean | $17.50 |
| Target Median | $16.00 |
| Target High | $31.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.22 | $-0.18 | 1.7% | +2.5% | 2↑ 1↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.20 | $-0.23 | $-0.18 | 3.2% | +2.4% | 3↑ 1↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.81 | $-0.91 | $-0.74 | 5.2% | +0.6% | 1↑ 4↓ | $0.0B | -100.0% | 6 |
| Next FY 2027-12-31 |
$-0.76 | $-0.93 | $-0.56 | 6.5% | +7.4% | 2↑ 1↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.197 | |
| 7d ago | $-0.202 | +0.005 |
| 30d ago | $-0.202 | +0.005 |
| 60d ago | $-0.214 | +0.017 |
| 90d ago | $-0.220 | +0.023 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 20, 2026 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
GNLX Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
<p align="center"><em>-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial </em><em>of Olvi-Vec expected in 2H
May 4, 2026
earnings_calendar
GNLX Q1 2026 Earnings Scheduled — 2026-05-04
Mar 19, 2026
earnings
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --</em></p> <p al
Mar 9, 2026
earnings_calendar
GNLX Q4 2025 Earnings Before Market Open — 2026-03-09